(R)-(+)-二氨基丙烷二盐酸盐

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (R)-(+)-二氨基丙烷二盐酸盐
• 中文别名: (R)-1,2-二氨基丙烷盐酸盐；(R)-(+)-二氨基丙烷盐酸盐；(R)-1,2-二氨基丙烷二盐酸盐；(R)-(-)-二氨基丙烷二盐酸盐
• 英文名称: Propane-1,2-diaminium dichloride
• 英文别名: [(2R)-1-azaniumylpropan-2-yl]azanium;dichloride
• 化学式: C3H12Cl2N2
• 分子量: 147.04
• InChiKey: AEIAMRMQKCPGJR-HWYNEVGZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.14
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  4
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-(+)-二氨基丙烷二盐酸盐 、 ethyl 2-phenylacetimidate hydrochloride 以70%的产率得到
  参考文献：
  名称：

  HSU F.-L.; HAMADA AKIHIKO; BOOHER M. E.; FUDER H.; PATIL P. N.; MILLER D.+, J. MED. CHEM., 1980, 23, NO 11, 1232-1235

  摘要：

  DOI：

文献信息

• SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS
  申请人：Kshirsagar Tushar A.

  公开号：US20090221551A1

  公开（公告）日：2009-09-03

  [1,2]Imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and imidazo[4,5-c]pyridines) substituted with a fused ring containing an oxygen and/or nitrogen atom attached at the 1- and/or 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本发明涉及[1,2]咪唑[4,5-c]环化合物（例如，咪唑[4,5-c]喹啉，咪唑[4,5-c]萘啉和咪唑[4,5-c]吡啶），其取代了一个含氧和/或氮原子的融合环，并连接在1-和/或2-位，以及含有这些化合物的药物组合物，中间体，制备这些化合物的方法以及将这些化合物用作免疫调节剂的方法，用于诱导动物体内的细胞因子生物合成，并用于治疗病毒性和肿瘤性疾病。
• AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE
  申请人：Raynham Tony Michael

  公开号：US20090247519A1

  公开（公告）日：2009-10-01

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.

  本发明涉及治疗化合物领域，更具体地涉及某些氨基乙基氨基芳基（AEAA）化合物，该化合物在其他方面抑制蛋白激酶D（PKD）（例如PKD1，PKD2，PKD3）。本发明还涉及包括这些化合物的制药组合物，以及在体外和体内使用这些化合物和组合物来抑制PKD，并用于治疗由PKD介导，通过抑制PKD改善的疾病和病况，包括增生性疾病如癌症等。
• NOVEL HETEROCYCLYL COMPOUNDS
  申请人：Adam Jean-Michel

  公开号：US20100022518A1

  公开（公告）日：2010-01-28

  The invention is concerned with novel heterocyclyl compounds of formula (I): wherein A, X, R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and may be used as medicaments.

  本发明涉及公式（I）的新异环烷化合物：其中A、X、R3、R4、R5、R6、R7、R8、R9、R10、m、n和p如说明书和权利要求所定义，以及其生理上可接受的盐。这些化合物是CCR2受体、CCR5受体和/或CCR3受体的拮抗剂，可用作药物。
• Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods
  申请人：3M Innovative Properties Company

  公开号：US08088788B2

  公开（公告）日：2012-01-03

  [1,2]Imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and imidazo[4,5-c]pyridines) substituted with a fused ring containing an oxygen and/or nitrogen atom attached at the 1- and/or 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本发明涉及1,2-取代咪唑并[4,5-c]环化合物（例如，咪唑并[4,5-c]喹啉，咪唑并[4,5-c]萘啉和咪唑并[4,5-c]吡啶），其被取代为在1-和/或2-位置附有一个氧和/或氮原子的融合环，以及含有这些化合物的制药组合物、中间体、制备这些化合物的方法和将这些化合物用作免疫调节剂的方法，用于在动物中诱导细胞因子生物合成以及治疗包括病毒和肿瘤疾病在内的疾病。
• Heterocyclyl compounds
  申请人：Hoffmann-La Roche Inc.

  公开号：US08138175B2

  公开（公告）日：2012-03-20

  The invention is concerned with novel heterocyclyl compounds of formula (I): wherein A, X, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and may be used as medicaments.

  本发明涉及式（I）的新型杂环化合物：其中A，X，R3，R4，R5，R6，R7，R8，R9，R10，m，n和p在说明书和权利要求书中已定义，并且其生理学上可接受的盐。这些化合物是CCR2受体，CCR5受体和/或CCR3受体的拮抗剂，可用作药物。